Learn how early cardiovascular autonomic neuropathy detection using the VitalScan ANS+ system improves risk stratification and patient outcomes in your cardiology practice.
Published October 13, 2026 · Updated November 5, 2026
Cardiovascular autonomic neuropathy (CAN) remains one of the most underdiagnosed yet clinically consequential complications in patients with diabetes and established cardiac disease. Despite clear recommendations from the American Diabetes Association (ADA) and the American Heart Association (AHA) regarding the prognostic weight of autonomic dysfunction, CAN detection is frequently overlooked until symptomatic presentation, such as orthostatic hypotension or resting tachycardia, occurs. By this stage, the window for effective intervention and mortality risk reduction has significantly narrowed.
Autonomic cardiac dysfunction serves as a robust, independent predictor of all-cause mortality and sudden cardiac death. In patients with cardiovascular disease, the loss of sympathetic and parasympathetic balance creates a pro-arrhythmic environment. Clinicians often focus on anatomical diagnostics—coronary angiography or echocardiography—while neglecting the neuro-regulatory aspect of cardiac stability. Early identification of CAN through standardized cardiac autonomic testing allows for a more comprehensive risk stratification, enabling cardiologists to identify patients who may require more aggressive glycemic control or tailored pharmacological management.
Historically, robust autonomic testing was relegated to specialized academic centers, often requiring prolonged protocols and specialized technicians. The VitalScan ANS+ system by US MedResources changes this paradigm, providing an FDA-cleared, non-invasive platform designed to integrate seamlessly into a standard cardiology workflow.
The VitalScan ANS+ provides a multidimensional view of a patient’s autonomic and vascular health in just 15 minutes. By utilizing standardized maneuvers and sensors, the system captures vital data points that are otherwise difficult to quantify:
For the busy cardiology practice, integrating autonomic assessment is not just a clinical imperative but a logical operational step. The VitalScan ANS+ system is designed to be administered by existing clinical staff, requiring no specialized technician. Because the system generates an automated, interpretive report immediately, providers can review actionable data before the patient leaves the office.
From a practice management perspective, the system supports robust clinical documentation and billing efficiency. Clinical activity performed using the VitalScan ANS+ falls under established CPT guidelines:
By incorporating this 15-minute diagnostic suite into annual physicals or chronic disease management follow-ups, cardiology practices can proactively manage patients before subclinical autonomic decline manifests as a major adverse cardiovascular event (MACE). The 30-year track record of US MedResources in autonomic diagnostic technology ensures that the data provided is reliable, reproducible, and ready for clinical decision-making.
Cardiovascular autonomic neuropathy detection is a vital component of modern cardiology, particularly for high-risk diabetic and heart failure populations. By utilizing the VitalScan ANS+ system, clinicians can bridge the gap between screening and diagnosis with an efficient, evidence-based tool that supports risk stratification, aligns with ADA and AHA guidelines, and provides measurable practice value. Moving beyond anatomical assessment to include autonomic and vascular function testing is essential to improving long-term outcomes for your most vulnerable patients.
One-Page Reference
Code descriptions, typical reimbursement ranges, ICD-10 pairings, and the CMS bundling note to check before you bill.
Combine cardiac autonomic testing with your vascular studies at your own volume and reimbursement, and see the annual figure.